United States-Mexico-Canada Trade Agreement, no specific bill. International Tax issues including regarding Public Law 115-97, Tax Cuts and Jobs Act
Tax issues related to Puerto Rico
Issues related to OECD negotiations on the taxation of global income S. 124 Preserve Access to Affordable Generics Act 
Issues related to drug patents and exclusivities (no bill)
H.R. 1520, Purple Book Continuity Act of 2019 
H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019
S. 1224, The Stop STALLING Act
S. 1416, The Affordable Prescriptions for Patients Act, on product hopping and patent thicketing
S.659 - the Biologics Patent Transparency Act
H.R. 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics 
H.R. 5133 Affordable Prescriptions for Patients Through Promoting Competition 
H.R. 3991 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
H.R. 2374 Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
H.R. 2375 Preserve Access to Affordable Generics and Biosimilars Act Biosimilars, no specific bill 
Prescription drug value issues, no specific bill 
FDA issues, no specific bill 
Issues related to International Pricing Index (IPI), no specific bill
S. 551 Recovering Excessive Funds for Unused and Needless Drugs Act
S. 657 Drug Price Transparency Act
S. 658 Accelerated Drug Approval for Prescription Therapies Act
S. 660 Efficiency and Transparency in Petitions Act
S. 1895, Lower Health Care Costs Act, a comprehensive bill designed to improve healthcare transparency and reduce healthcare costs, including prescription drugs
S. 1391, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act
H.R. 1499, Protecting Consumer Access Generic Drugs Act
H.R. 1344, Competitive Deals Resulting in Unleashed Generics and Savings (DRUGS) Act
S. 1169, Ensuring Timely Access to Generics Act
S. 1617, Second Look at Drug Patents Act
H.R. 1520, Purple Book Continuity Act
S. 1209, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act
S. 977, Transparent Drug Pricing Act 
S. 102, Prescription Drug Price Relief Act
S. 659, Biologic Patent Transparency Act
H.R. 1503, Orange Book Transparency Act
H.R. 2296, Fair Accountability and Innovative Research (FAIR) Drug Pricing Act
S. 1664, Prescription Drug Price Reporting Act
S.659 - the Biologics Patent Transparency Act Medicare Part B coverage and reimbursement issues 
Issues related to International Pricing Index (IPI), no specific bill
Coding and reimbursement for biologics/biosimilars
Issues related to Part D redesign, no specific bill
Issues related to Part D rebate reform, no specific bill
Medicare Part D access issues for plan year 2020, no specific bill
S. 1676 Chronic Kidney Disease Improvement in Research and Treatment Act; Transitional drug add-on payment (TDAPA), dialysis bundled payment system issues
H.R. 2296/S 1391 FAIR Drug Pricing Act
S. 1416 Affordable Prescriptions for Patients Act
Issues related to Direct to Consumer Advertisement
S. 551, Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act
Issues related to Biosimilars, no specific bill 
Prescription drug value issues, no specific bill 
S. 1664, Prescription Drug Price Reporting Act
H.R. 3 - Lower Prescription Drug Costs Now Act
H.R. 2693/S. 283 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2019
Issues related to the Center for Medicare & Medicaid Innovation
S. 2543 Prescription Drug Pricing Reduction Act
Section 210- Applying Medicaid Drug Rebate Requirement to Drugs Provided as Part of Outpatient Hospital Services
H.R. 19/S. 3129 Lower Costs, More Cures Act
S. 3013 Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
TRD - Trade (domestic/foreign) TAX - Taxation/Internal Revenue Code CPT - Copyright/Patent/Trademark HCR - Health Issues MMM - Medicare/Medicaid
136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 11 - Executive Office of the President (EOP) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 198 - Natl Economic Council (NEC) 18 - Office of Management & Budget (OMB) 1 - SENATE
AMGEN, INC.
601 13th Street, NW, 11th Floor North, WASHINGTON, DC, 20005, US
L NICOLE CURRIE HOWARD MOON JESSE KERNS HELEN RHEE VICTORIA BLATTER WILLIAM O'BRIEN GREGORY PORTNER JORDAN LYNN LAYSON L NICOLE CURRIE JORDAN LYNN LAYSON HELEN RHEE GREGORY PORTNER L NICOLE CURRIE WILLIAM O'BRIEN REBECCA MANDELL VICTORIA BLATTER HOWARD MOON JESSE KERNS JORDAN LYNN LAYSON WILLIAM O'BRIEN HELEN RHEE REBECCA MANDELL JESSE KERNS L NICOLE CURRIE GREGORY PORTNER VICTORIA BLATTER HOWARD MOON RUTH HOFFMAN L NICOLE CURRIE GREGORY PORTNER HELEN RHEE REBECCA MANDELL JESSE KERNS VICTORIA BLATTER WILLIAM O'BRIEN HOWARD MOON RUTH HOFFMAN JORDAN LYNN LAYSON